Literature DB >> 2415689

Ataxia-telangiectasia: an overview.

E Boder.   

Abstract

The more subtle clinical findings that facilitate early diagnosis and the most provocative long-term clinical observations in our series of patients are emphasized. The most striking pathological findings in our own series of 11 complete autopsies are reviewed in relation to new findings from 57 autopsy reports in the recent literature. Clinical and pathological findings in our oldest patient, who died at age 32, are systematically compared with those of her sister, who died 20 years earlier at age 10 1/2 and who was the subject of the first autopsy in AT, thus providing a rare comparison of the early and late stages of the disease. The clinical and pathological findings, including the gliovascular malformations in the CNS described recently in autopsies on older patients, reveal that AT is characterized throughout its course by multisystemic progeric changes. It is proposed, therefore, that AT can serve as a model for the study of premature aging. Clinical diagnosis, laboratory markers, and special diagnostic procedures, along with general management, immunotherapy, and rehabilitative measures, are reviewed in Part II.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2415689

Source DB:  PubMed          Journal:  Kroc Found Ser        ISSN: 0361-0489


  28 in total

1.  ATM and the DNA damage response. Workshop on ataxia-telangiectasia and related syndromes.

Authors:  Martin F Lavin; Domenico Delia; Luciana Chessa
Journal:  EMBO Rep       Date:  2006-02       Impact factor: 8.807

2.  Evidence for an elevated frequency of in vivo somatic cell mutations in ataxia telangiectasia.

Authors:  W L Bigbee; R G Langlois; M Swift; R H Jensen
Journal:  Am J Hum Genet       Date:  1989-03       Impact factor: 11.025

3.  Mutation of ataxia-telangiectasia mutated is associated with dysfunctional glutathione homeostasis in cerebellar astroglia.

Authors:  Andrew Campbell; Jared Bushman; Joshua Munger; Mark Noble; Christoph Pröschel; Margot Mayer-Pröschel
Journal:  Glia       Date:  2015-10-15       Impact factor: 7.452

4.  The ATM cofactor ATMIN protects against oxidative stress and accumulation of DNA damage in the aging brain.

Authors:  Nnennaya Kanu; Kay Penicud; Mariya Hristova; Barnaby Wong; Elaine Irvine; Florian Plattner; Gennadij Raivich; Axel Behrens
Journal:  J Biol Chem       Date:  2010-10-02       Impact factor: 5.157

5.  Molecular defects in Moroccan patients with ataxia-telangiectasia.

Authors:  L Jeddane; F Ailal; C Dubois-d'Enghien; O Abidi; I Benhsaien; A Kili; S Chaouki; Y Kriouile; N El Hafidi; H Fadil; R Abilkassem; N Rada; A A Bousfiha; A Barakat; D Stoppa-Lyonnet; H Bellaoui
Journal:  Neuromolecular Med       Date:  2013-01-16       Impact factor: 3.843

6.  Tumor suppressor ataxia telangiectasia mutated functions downstream of TGF-β1 in orchestrating profibrotic responses.

Authors:  Jessica M Overstreet; Rohan Samarakoon; Diana Cardona-Grau; Roel Goldschmeding; Paul J Higgins
Journal:  FASEB J       Date:  2014-12-05       Impact factor: 5.191

7.  ISG15 deregulates autophagy in genotoxin-treated ataxia telangiectasia cells.

Authors:  Shyamal D Desai; Ryan E Reed; Shilka Babu; Eric A Lorio
Journal:  J Biol Chem       Date:  2012-12-04       Impact factor: 5.157

8.  Effects of antioxidants on cancer prevention and neuromotor performance in Atm deficient mice.

Authors:  Ramune Reliene; Sheila M Fleming; Marie-Françoise Chesselet; Robert H Schiestl
Journal:  Food Chem Toxicol       Date:  2007-08-29       Impact factor: 6.023

9.  Extracerebellar MRI-lesions in ataxia telangiectasia go along with deficiency of the GH/IGF-1 axis, markedly reduced body weight, high ataxia scores and advanced age.

Authors:  Matthias Kieslich; Franziska Hoche; Janine Reichenbach; Stefan Weidauer; Luciana Porto; Stefan Vlaho; Ralf Schubert; Stefan Zielen
Journal:  Cerebellum       Date:  2010-06       Impact factor: 3.847

Review 10.  Fanconi Anemia Signaling and Cancer.

Authors:  Manoj Nepal; Raymond Che; Jun Zhang; Chi Ma; Peiwen Fei
Journal:  Trends Cancer       Date:  2017-11-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.